Blood · 2012 · 70 citations · 36 references
Life SciencesCell BiologyImmunologyCell SignalingImmunoregulationSignal TransductionAngiogenesisEndothelial ActivationGrowth Factor SignalingLymphatic MicroenvironmentLymphoid TissueLymphatic Endothelial Cell BiologyLymphatic Endothelial Cell FunctionLymphatic Endothelial Cell SignalingLymphatic Endothelial CellsLymphatic Endothelial Function
LYVE-1 (lymphatic vessel endothelial hyaluronan receptor-1) is a homolog of the hyaluronan receptor CD44, and one of the most widely used markers of lymphatic endothelial cells in normal and tumor tissues. However, the physiologic role of LYVE-1 in the lymphatic system still remains unclear. It is well established that fibroblast growth factor 2 (FGF2) induces lymphangiogenesis. Based on the known interaction between FGF2 and CD44 and based on the structural similarity of CD44 and LYVE-1, we investigated whether FGF2 might interact with LYVE-1. We found that FGF2 is able to bind LYVE-1 using AlphaScreen, or after surface-immobilization or in solution. FGF2 binds to LYVE-1 with a higher affinity than any other known LYVE-1–binding molecules, such as hyaluronan or PDGF-BB. Glycosylation of LYVE-1 is important for FGF2 binding. Furthermore, FGF2 interacts with LYVE-1 when overexpressed in CHO cells. Soluble LYVE-1 and knockdown of LYVE-1 in lymphatic endothelial cells impaired FGF2 signaling and functions. In addition, FGF2 but not VEGF-C-induced in vivo lymphangiogenesis, was also inhibited. Conversely, FGF2 also modulates LYVE-1 expression in cells and ex vivo. Thus, our data demonstrate a functional relationship to the interaction between FGF2 and LYVE-1.
36
PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis
Renhai Cao, Meit A. Björndahl, Piotr Religa et al. · Cancer Cell · 2004 · 529 citations
Medicine, Cancer Biology, Oncology +14
Moosa Mohammadi, Andrey Sorokin, Wilson H. Burgess et al. · Molecular and Cellular Biology · 1996 · 386 citations · Full text